Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$150.47 USD
-0.90 (-0.59%)
Updated May 10, 2024 04:00 PM ET
After-Market: $150.50 +0.03 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Brokerage Reports
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 401 - 407 ( 407 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alnylam continues to extend its dominance in RNAi IP: additional Tuschl II patent granted
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Nature Biotechnology paper offers further validation for Regulus'' microRNA platform
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alnylam continues to execute and capitalize on its partnerships; gets $20M from Takeda
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S